EyePoint Pharmaceuticals Files 8-K

Ticker: EYPT · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1314102

Eyepoint Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyEyepoint Pharmaceuticals, Inc. (EYPT)
Form Type8-K
Filed DateJun 26, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: listing, sec-filing

Related Tickers: EYPT

TL;DR

EYPT's 8-K filed 6/26/24 confirms Nasdaq listing. Standard disclosure.

AI Summary

EyePoint Pharmaceuticals, Inc. reported on June 26, 2024, that its common stock is trading on The Nasdaq Global Market under the symbol EYPT. The company is incorporated in Delaware and its principal executive offices are located in Watertown, Massachusetts. This filing is a routine current report, indicating no specific material events beyond standard disclosures.

Why It Matters

This 8-K filing confirms EyePoint Pharmaceuticals' listing on the Nasdaq Global Market, which is crucial for its public trading and investor relations.

Risk Assessment

Risk Level: low — This filing is a standard current report with no new material events, debt, or significant financial changes disclosed.

Key Players & Entities

  • EyePoint Pharmaceuticals, Inc. (company) — Registrant
  • June 26, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Watertown, Massachusetts (location) — Principal executive offices
  • EYPT (ticker) — Trading Symbol for Common Stock
  • The Nasdaq Global Market (exchange) — Name of exchange where common stock is registered

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report current information about EyePoint Pharmaceuticals, Inc. as required by the Securities and Exchange Commission, including its listing on The Nasdaq Global Market.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 26, 2024.

What is the trading symbol for EyePoint Pharmaceuticals, Inc.'s common stock?

The trading symbol for EyePoint Pharmaceuticals, Inc.'s common stock is EYPT.

On which exchange is EyePoint Pharmaceuticals, Inc.'s common stock registered?

EyePoint Pharmaceuticals, Inc.'s common stock is registered on The Nasdaq Global Market.

Where are EyePoint Pharmaceuticals, Inc.'s principal executive offices located?

EyePoint Pharmaceuticals, Inc.'s principal executive offices are located at 480 Pleasant Street, Watertown, Massachusetts, 02472.

Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-26 09:25:24

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On June 26, 2024, EyePoint Pharmaceuticals, Inc. (the "Company") posted the Company's 2024 R&D Day Presentation (the "Presentation") on its website at www.eyepointpharma.com , which Presentation included the Company's estimated cash and investments on hand as of June 30, 2024 and certain other corporate updates. The amounts included in the Presentation were calculated prior to the completion of a review by the Company's independent registered public accounting firm and are therefore subject to change upon completion of the Company's quarterly report for the period ended June 30, 2024. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of June 30, 2024.

01 Other Events

Item 8.01 Other Events. A copy of the Presentation is filed as Exhibit 99.1 hereto and is incorporated by reference herein. On June 26, 2024, the Company issued a press release announcing certain clinical and regulatory developments for its lead pipeline program, DURAVYU (vorolanib intravitreal insert), formerly known as EYP-1901, its Durasert E sustained drug delivery technology and early-stage programs to be presented during the Company's R&D Day. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 R&D Presentation of EyePoint Pharmaceuticals, Inc. dated June 26, 2024 99.2 Press Release of EyePoint Pharmaceuticals, Inc. dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: June 26, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.